Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;67(4):382-386.
doi: 10.1007/s10384-023-00992-x. Epub 2023 May 4.

Association between treatment for retinopathy of prematurity and blood monocyte counts

Shumpei Obata  1 , Riko Matsumoto  2 , Masashi Kakinoki  2 , Osamu Sawada  2 , Tomoko Sawada  2 , Yoshitsugu Saishin  2 , Takahide Yanagi  3 , Yoshihiro Maruo  3 , Masahito Ohji  2
Affiliations

Association between treatment for retinopathy of prematurity and blood monocyte counts

Shumpei Obata et al. Jpn J Ophthalmol. 2023 Jul.

Abstract

Purpose: To investigate blood monocyte counts as a risk factor for retinopathy of prematurity (ROP) treatment.

Design: Retrospective cohort study.

Methods: Infants who underwent ROP screening at Shiga University of Medical Science Hospital between January, 2011 and July, 2021 were included in this study. Screening criteria were a gestational age (GA) < 32 weeks or birth weight (BW) < 1500 g. The week with the largest difference in monocyte counts between the infants with and without type 1 ROP determined based on the effect size. Multivariate logistic regression analysis was applied to investigate whether the monocyte counts constituted an independent risk factor for type 1 ROP. The objective variable was type 1 ROP, and the explanatory variables were GA, BW, infants' infection, and Apgar score at 1 min and monocyte counts in the week with the largest monocyte-counts difference between the with- and without type 1 ROP groups.

Results: In total, 231 infants met the inclusion criteria. The monocyte counts in the fourth week after birth (4w MONO) exhibited the largest difference between infants with and without type 1 ROP. The analysis was performed on 198 infants, excluding 33 infants without 4w MONO data. Thirty-one infants had type 1 ROP, whereas 167 infants did not. BW and 4w MONO were significantly associated with type 1 ROP (odds ratio: 0.52 and 3.9, P < .001 and 0.004, respectively).

Conclusions: The 4w MONO was an independent risk factor for type 1 ROP and may be useful in follow-up of infants with ROP.

Keywords: Monocyte; Retinopathy of prematurity; Risk factor; Treatment.

PubMed Disclaimer

References

    1. Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev. 2008;84:77–82. - DOI - PubMed
    1. Lyu J, Zhang Q, Jin H, Xu Y, Chen C, Ji X, et al. Aqueous cytokine levels associated with severity of type 1 retinopathy of prematurity and treatment response to ranibizumab. Graefes Arch Clin Exp Ophthalmol. 2018;256:1469–77. - DOI - PubMed
    1. Sato T, Kusaka S, Shimojo H, Fujikado T. Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. Ophthalmology. 2009;116:2165–9. - DOI - PubMed
    1. Hu YX, Xu XX, Shao Y, Yuan GL, Mei F, Zhou Q, et al. The prognostic value of lymphocyte-to-monocyte ratio in retinopathy of prematurity. Int J Ophthalmol. 2017;10:1716–21. - PubMed - PMC
    1. Early Treatment For Retinopathy Of Prematurity Cooperative G. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684–94. - DOI

LinkOut - more resources